Systems, apparatus and methods including a contact lens that facilitates collection and/or processing of information associated with sensed features are provided. In one aspect, a system can include a contact lens and an analysis component external to the contact lens. The contact lens can include: a substrate; and a circuit, disposed on or within the substrate. The circuit can include: a plurality of sensors configured to sense respective features associated with a wearer of the contact lens; and a communication component configured to communicate information indicative of sensed features. The analysis component can be configured to: receive the information indicative of the sensed features; and generate statistical information based, at least, on the information indicative of the sensed features.

Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

A protocol for assessing the prognosis for a patient diagnosed with a neoplasm or suspected of having a neoplasm is provided herein. The protocol involves the steps of determining a mitotic cells to proliferating cells ratio (M:P ratio) in a neoplastic tissue sample obtained from the patient and producing a prognosis for the neoplasm based on the M:P ratio.

The present invention relates generally to the field of human genetics. More specifically, this invention relates to the clinical application of a bioinformatics methodology described in patent application Ser. No. 14/154,303 for the early detection of cancer. Said clinical application relates to obtaining the genome sequence from an individual's healthy tissue and comparing it to the DNA sequence obtained from that same individual's body tissues, wastes and/or fluids. Said method inspects the DNA sequence obtained from body tissues, wastes and/or fluids for the presence of DNA damage at bioinformatically predicted genetically unstable loci within cancer-linked regions of the patients healthy DNA. The identification of DNA damage within a predicted locus is considered to be evidence of cancer. Said method then uses the unique signature of any damaged DNA sequence which has occurred at predicted unstable cancer-linked loci to construct patient-specific cancer biomarker(s). These biomarkers can be used for monitoring the progression of cancer and for treatment of the cancer in a patient.

The present disclosure provides a method for qualifying a subject for a subset of therapies. The medical history data and biologic data may be received for the subject wherein the biologic data is generated from one or more biological samples of the subject. Then, the medical history data and the biologic data may be computer analyzed to yield a genomic-based medical history analysis for the subject. The genomic-based medical history analysis may be used for the subject to query one or more databases of therapies for the subject, to generate the subset of therapies for which the subject qualifies. The subset of therapies may be provided on a user interface on an electronic device of a user

A system and method for genotyping tandem repeats in sequencing data. The invention uses Bayesian model selection guided by an empirically-derived error model that incorporates properties of sequence reads and reference sequences to which they map.

Various medical systems and methods are described, including a medical monitoring system. The medical monitoring system can have a fluid system configured to receive bodily fluid and optically analyze said fluid to determine analyte concentration. The fluid system can have a removable portion. The removable portion can have an opening with a port. The system can also have a container configured to contain anticoagulant. The container can have a portion configured to mate with the port of the removable portion. The container can be further configured to not fit into a conventional luer fitting. An anti-coagulant insertion apparatus is also described. The apparatus can have a syringe, a dock with a port, and an adapter configured to connect the syringe to the port. The dock can also have a tab configured to move with the port.

The present invention covers the integration and utility of accelerometer features into a clinical analysis system. For example, measurement of dynamic acceleration and orientation of a blood-testing instrument with respect to Earth's gravitational field may be used to determine reliability of a test procedure and optionally to provide corrective elements thereof.

An apparatus determines patterns of occurrence of compound variables based on a set of mathematical interactions and patterns of occurrence of a set of electrical signals. Then, the apparatus calculates statistical relationships corresponding to a pattern of occurrence of neural activity of one or more organisms and the patterns of occurrence of the compound variables. Moreover, the apparatus determines numbers of occurrences of electrical signals that were used to determine compound variables in at least a statistically significant subset of the compound variables, and determines numbers of different mathematical interactions that were used to determine the compound variables in the subset for the electrical signals that are associated with the corresponding numbers of occurrences. Next, the apparatus identifies one or more of the electrical signals as one or more association variables based on the numbers of occurrences and/or the numbers of different mathematical interactions.

A system is disclosed that enables the automated measurement of cellular mechanical parameters at high throughputs. The microfluidic device uses intersecting flows to create an extensional flow region where the cells undergo controlled stretching. Cells are focused into streamlines prior to entering the extensional flow region. In the extensional region, each cell's deformation is measured with an imaging device. Automated image analysis extracts a range of independent biomechanical parameters from the images. These may include cell size, deformability, and circularity. The single cell data that is obtained may then be used to in a variety of ways. Scatter density plots of deformability and circularity may be developed and displayed for the user. Mechanical parameters such as deformability and circularity may be gated or thresholded to identify certain cells of interest or sub-populations of interest. Similarly, the mechanical data obtained using the device may be used as cell signatures.